


# Major shifts in new ACT-A Strategy & Budget

## Facilitation Council Technical Briefing

---

22 SEPTEMBER 2021

ACT now. ACT together to accelerate the end of the COVID-19 crisis



## The new ACT-A context...

The **fight against COVID-19** has fundamentally changed since ACT-A's launch

**From virtually no countermeasures** to the development, scale-up & deployment of a range of tools, especially vaccines

## BUT...


**uneven access & fragile progress = a '2 track pandemic'** with dramatically different health, economic & societal impacts,

**global agreement about the epidemiological situation**

- a) continued oscillations in next 6m,
- b) min global immunity through e.g., vaccines is needed to end the acute phase of the pandemic,
- c) COVID-19 will be with us for the long-term

**ACT-A is operating in a dramatically different environment** with many actors now working to accelerate access to tools & market forces influencing equity

## New focus | ACT-A's next 12 month strategy (Oct '21-Sept '22) will reflect the rapidly evolving global COVID-19 context




As the only global, end-to-end solution for developing & scaling COVID-19 tools, ACT-A is uniquely positioned to advance this objective.

# ACT-A's work will be driven by **clear targets & real-time understanding of coverage gaps**

## Vaccines coverage

(% of population fully vaccinated)


**Global target:** 70% coverage



## Diagnostics coverage

(Average daily tests for COVID-19)

**Global target:** 100 tests/100K pop/day in all countries



Work ongoing to define contribution of ACT-A towards wider global targets for vaccines, tests, treatments & PPE

# New strategic priorities will anchor ACT-A's work to 'solve the escalating inequity'

## ENABLING PRIORITY:

- 1** **Closely track gaps and crucial barriers to access Vaccines, Tests & Treatments**  
esp. in LICs, LMICs & lagging UMICs to direct ACT-A work & accelerate equity

## PRODUCT PRIORITIES:


- 2** **Accelerate the 70% global vaccination target**, tackling barriers to development, global access and uptake
- 3** **Ensure key testing & sequencing capacities globally**, to track evolving epi & virus; optimise use of tools
- 4** **Save & protect lives**, with scaled delivery of existing & new treatments, incl. O2, and access to PPE

## DELIVERY PRIORITY:

- 5** **Fully integrate Pillar delivery support with COVID-19 global, regional & national response mechanisms**,  
(integrating vulnerabilities, financing & risks, and managing interface with health systems)


# Total estimated cost for LICs/LMICs for next 12 months | to track the pandemic, reach global Vx targets, save lives & protect HCWs = ~US\$ 50B

*Cost estimates for LICs/LMICs+ by category of cost in US\$ Bn*




Work in progress on the crucial investments to fully leverage ACT-A's added value

**ACT-A sits within the global response, and will focus its contribution on closing the equitable access gap and managing risks**




# Differentiating ACT-A funding needs to ensure the investments needed to close equity gaps and mitigate risks

ACT-A's 2021/22 budget compared to global financing targets, US\$ Billion





## Timeline & next steps | publish new ACT-A Strategic Plan & Budget in advance of the G20 Summit



### Immediate next steps

- Pillars continuing to sharpen targets, priorities & budgets
- Hub consolidating Pillar inputs into overall draft
- Pillars/Hub incorporating Strategic Review findings